Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice |
| |
| Authors: | Richard W. Joseph Gurkamal Chatta Ulka Vaishampayan |
| |
| Affiliation: | 1. Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL;2. Clinical Chief for Genitourinary Medicine, Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY;3. Professor of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI |
| |
| Abstract: | BackgroundNivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy.Methods and PurposeThis commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management. |
| |
| Keywords: | Advanced renal cell carcinoma Immune checkpoint inhibitor Immunotherapy agents Nivolumab Second-line therapy PD-1 inhibitor |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
